This Novel, Non-Amyloid Approach to Alzheimer’s Therapy Could Vastly Improve Outcomes
Immunology-focused pharma company INmune Bio is set to start first-in-man clinical trials with a promising anti-TNF compound that could revolutionize the treatment of Alzheimer’s disease and related symptoms
























